Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396073 | 0.91 | EPHX1 (0.57) | EPHX1ALDH1A1 | |
| SCHEMBL12897266 | 0.85 | KMT2A (0.37) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL10858150 | 0.81 | EPHX1 (0.46) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL13294283 | 0.81 | EPHX1 (0.60) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL3684347 | 0.81 | EPHX1 (0.60) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL7544684 | 0.81 | EPHX1 (0.48) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL31354485 | 0.80 | ALDH1A1 (0.32) | EPHX1ALDH1A1 | |
| SCHEMBL30159877 | 0.78 | LMNA (0.40) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL16589328 | 0.78 | EPHX1 (0.44) | EPHX1HPGDTP53ALOX12LMNA | |
| SCHEMBL7872734 | 0.77 | ALDH1A1 (0.50) | EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615526-B2 | Furanoid and pyranoid C14-C18- oxabicycloalkanones as odoriferous and/or aroma substances | SYMRISE GMBH & CO. KG (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20080234174-A1 | FURANOID AND PYRANOID C14-C18- OXABICYCLOALKANONES AS ODORIFEROUS AND/OR AROMA SUBSTANCES | SYMRISE GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234174-A1 | FURANOID AND PYRANOID C14-C18- OXABICYCLOALKANONES AS ODORIFEROUS AND/OR AROMA SUBSTANCES | CYP19A1, OXER1, AKR1C4 | EPHX1 298/4885HPGD 64/4885TP53 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.